Yeast Peptide-Hydroxytyrosol Complex for Ischemic Stroke Oxidative Damage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for stroke, such as thrombolytic therapy, antiplatelet therapy, and neuroprotective drugs, have limitations including a narrow treatment window, bleeding risks, side effects, and limited efficacy, while polypeptides face challenges like bioactivity loss and toxic residues, necessitating the development of safer and more effective stroke treatments.
Innovation Solution
A complex comprising a yeast peptide with a molecular weight less than 3 kDa, prepared by papain enzymolysis under specific conditions, combined with hydroxytyrosol and optionally lecithin or a phospholipid membrane, demonstrates therapeutic effects on ischemic stroke by alleviating oxidative damage during ischemia-reperfusion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If thrombolytic therapy is used to treat stroke, then the treatment effectiveness is improved, but the risk of bleeding increases
Solution Approach 1:
The patent uses yeast peptides as an intermediary substance that mediates between the need for effective stroke treatment and the risk of bleeding. The yeast peptide acts as a natural thrombolytic agent that dissolves blood clots while having a safer profile compared to conventional thrombolytic drugs, thereby reducing bleeding risks while maintaining treatment effectiveness
Solution Approach 2:
The patent employs yeast peptides which are derived from yeast protein through enzymatic hydrolysis. These peptides are relatively short-lived in the body and can be continuously administered if needed, providing a safer alternative to long-acting conventional thrombolytics that carry higher bleeding risks
2Reliability
If polypeptides are used for stroke treatment, then the therapeutic effect is improved, but the bioactivity may be lost during digestion
Solution Approach 1:
The patent segments the yeast protein into smaller peptide fragments through enzymatic hydrolysis using papain. This segmentation creates peptides with molecular weights primarily between 1-3 kDa, which are small enough to resist degradation by digestive enzymes while retaining their therapeutic bioactivity. The segmented structure allows the peptides to survive digestion and reach the target site effectively
Solution Approach 2:
The patent changes the molecular weight parameter of the peptide fragments by controlling the enzymatic hydrolysis process. By optimizing the hydrolysis conditions (papain to yeast protein ratio of 8800-9200 U/g, pH 6.8-7.2, temperature 48-58°C, time 3.8-6.2 hours), the patent produces peptides with specific molecular weight characteristics that enhance stability against digestive enzymes while preserving therapeutic activity
3Adaptability or versatility
If conventional neuroprotective drugs are used, then the treatment coverage is improved, but the efficacy is limited
Solution Approach 1:
The patent creates a composite therapeutic approach by combining yeast peptides with hydroxytyrosol. This composite formulation synergistically combines the thrombolytic effects of yeast peptides with the antioxidant and neuroprotective properties of hydroxytyrosol, thereby enhancing overall efficacy while maintaining broad treatment coverage for different stroke scenarios
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The yeast peptide-hydroxytyrosol complex significantly reduces cerebral infarction area and improves neurological scores in mice, enhancing superoxide dismutase activity and antioxidant glutathione content without toxic side effects, offering a safer and more effective therapeutic option.
Implementation Method 1
the yeast peptide is a yeast peptide with a molecular weight less than 3 kDa produced by papain enzymolysis of a yeast protein
Implementation Method 2
Introducing lecithin or a phospholipid membrane into the complex can promote the binding of the yeast peptide and the hydroxytyrosol
Data Source
AI summary
The present invention discloses a complex with a stroke therapeutic characteristic, and a preparation method and use thereof. The complex is a complex of a yeast peptide and hydroxytyrosol. The yeast peptide is a yeast peptide with a molecular weight less than 3 kDa produced by papain enzymolysis of yeast protein. The pH during enzymatic hydrolysis is 6.8-7.2, the enzymatic hydrolysis time is 3.8-6.2 h, the enzymatic hydrolysis temperature is 48-58° C., and the ratio of the papain to the yeast protein in the enzymatic hydrolysis system is 8,800-9,200 U/g. The complex is used for manufacture of a drug for treating ischemic stroke. The present invention offers an efficient, safe, and cost-effective complex with a stroke therapeutic characteristic, featuring broad application prospects, and significant technical advantages, and the complex has a simple preparation method and low production cost.